Cover Image

Not for Sale

View/Hide Left Panel

Purcell, R.H. 1984. Personal communication, National Institutes of Health, Bethesda, Md.

Robbins, J. 1984. Personal communication, National Institutes of Health, Bethesda, Md.

Ruben, F.L. 1984. Personal communication, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Penn.

Shapiro, M.E., A.B.Onderan, D.L.Kasper, and R.W.Finberg. 1982. Cellular immunity to Bacterioides fragilis capsular polysaccharide. J. Exp. Med. 155:1188–1197.

Sheagren, J.N. 1984a. Staphylococcus aureus. The persistent pathogen (part 1). N. Engl. J. Med. 310(21):1368–1373.

Sheagren, J.N. 1984b. Staphylococcus aureus. The persistent pathogen (part 2). N. Engl. J. Med. 310(22):1437–1442.

Soderstrom, T., G.Hansson, and G.Larson. 1984. The Escherichia coli K1 capsule shares antigenic determinants with the human gangliosides GM3 and GD3. N. Engl. J. Med. 310(11):726–727.

Spencer, R.R., and Parker, R.R. 1924. Rocky Mountain Spotted Fever: Experimental studies on tick virus. Pub. Health Rep. 39:3027–3040.

Steere, A.C., R.L.Grodzicki, A.N.Kornblatt, J.E.Croft, A.G.Barbour, W.Burgdorfer, G.P.Schmid, E.Johnson, and S.E.Malawista. 1983. The spirochetal etiology of Lyme disease. N. Engl. J. Med. 308(13):733–740.

Washington, J.A. 1971. Comparison of two commonly used animal models for detection of bacterimia. Applied Microbiol. 22:604–607.

Wenzel, R.P., R.B.Craven, J.A.Davies, J.O.Hendley, H.B.Hamory, and J.M.Gwaltney, Jr. 1976. Field trial of an inactivated Mycoplasma pneumoniae vaccine. I. Vaccine efficacy. J. Infect. Dis. 134(6): 571–576.

Wong, K.H., W.D.Schalla, R.J.Arko, J.C.Bullard, and J.C.Feeley. 1979. Immunochemical, serologic, and immunologic properties of the major antigens isolated from the Legionnaire’s disease bacterium: Observations bearing on the feasibility of a vaccine. Ann. Int. Med. 90(4):634–638.

Wyle, F.A., M.S.Artenstein, B.L.Brandt, E.C.Tramont, D.L.Kasper, P.L.Altieri, S.L.Berman, and J.P.Lowenthal. 1972. Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. 126(4):514–521.

Zollinger, W.D., and R.E.Mandrell. 1983. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40(1):257–264.

Zollinger, W.D., R.E.Mandrell, J.M.Griffiss, P.Altieri, and S.Berman. 1979. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J. Clin. invest. 63(5):836–848.

Zollinger, W.D., R.E.Mandrell, and J.M.Griffiss. 1982. Enhancement of immunologic activity by noncovalent complexing of meningococcal group B polysaccharide and outer membrane proteins. Pp. 254–262 in Seminars in Infectious Disease. Volume IV: Bacterial Infections, L.Weinstein and B.N.Fields, eds. New York: Thieme-Stratton.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement